Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man Max 99 years
Merckle GmbH
Update Il y a 4 ans
A randomized, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly patients with aggressive B cell Non-HOdgkin lymphomas at hIgh risk for R-CHOP-21-inDuced neutropenia – AVOID Neutropenia
The primary objective of this study is to demonstrate non-inferiority of lipegfilgrastim (Lonquex, Teva) vs. pegfilgrastim (Neulasta®, Amgen) for the duration of severe neutropenia (DSN) in the first ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Serono International S.A
Update Il y a 4 ans
A phase II, multicentre, randomised, assessor.blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f) in oligo-anovulatory infertile women undergoing ovulation induction (OI)
The primary objective: Identify the optimal dose of AS900672- Enriched to induce ovulation in oligo-anovulatory infertile women.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients Followed by a 1-Year Extension
In obese patients, (1) to assess the effects of 2 or 4 mg MK-0364 after 1 year of treatment on body weight; (2) to assess the safety and tolerability of MK-0364 during base and extension studies.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck KGaA
Update Il y a 4 ans
A study to compare Pergoveris and GONAL-f in women who have responded poorly to previous infertiliy treatment cycles
The primary objective of the trial is to demonstrate superiority of Pergoveris® versus GONAL-f® in poor ovarian response (POR) patients.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Laboratoires Merck Sharp & Dohme - Chibret
Update Il y a 4 ans
A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
(1) To assess the effect of treatment with MK-0893 in combination with sitagliptin or metformin compared with sitagliptin in combination with metformin on 24-hour weighted mean glucose (WMG) after 4 w...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
IMI/REL (MK-7655A) vs. CMS + IMI in Subjects with Imipenem-Resistant Bacterial Infection
(1) To estimate the proportion of subjects with favorable overall response to IMI/MK-7655 (Treatment Group 1 only) and to CMS + IMI (Treatment Group 2). The overall response will be estimated based o...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Laboratoires Merck Sharp & Dohme - Chibret
Update Il y a 4 ans
Multicenter, open, pragmatic, randomized trial comparing the efficacy of 3 different lifestyle interventions after addition of sitagliptin to patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin therapy
After addition of Sitagliptin (JANUVIA®) to outpatients with T2DM who have inadequate glycemic control on metformin therapy - To compare the efficacy of three strategies of lifestyle changes associa...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck
Update Il y a 4 ans
CORE : Essai de phase 2, randomisé, évaluant l’efficacité et la tolérance de deux schémas d’administration du cilengitide associé à un traitement standard par témozolomide et radiothérapie concomitante suivi par témozolomide en traitement d’entretien, chez des patients ayant un glioblastome multiforme avec un promoteur du gène MGMT non méthylé. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité de deux schémas d’administration du cilengitide associé à un traitement standard par radiothérapie et témozolomide, chez des patients ayant un gliobl...
Country
France
organs
Cerveau
Specialty
Chimiothérapie
,
Radiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Laboratoires Merck Sharp & Dohme - Chibret
Update Il y a 4 ans
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic Cell Tranplants (HCTs)
To assess the safety and tolerability of the heat-treated varicella-zoster vaccine (VZV) vaccine in recipients of autologous hematopoietic cell transplant (HCT). To assess the impact of the heat-treat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
To define the objective response rate associated with the administration of vorinostat in combination with bortezomib to patients with relapsed or refractory multiple myeloma after at least 2 prior tr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
11
12
13
14
15
16
17
18
19
20
Next